| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nicotine | 26 | 2025 | 144 | 6.060 |
Why?
|
| Electronic Nicotine Delivery Systems | 11 | 2025 | 58 | 4.760 |
Why?
|
| Cushing Syndrome | 18 | 2020 | 23 | 3.160 |
Why?
|
| Male | 88 | 2025 | 3671 | 2.970 |
Why?
|
| Animals | 82 | 2025 | 1875 | 2.890 |
Why?
|
| Stress, Psychological | 5 | 2025 | 60 | 2.810 |
Why?
|
| Mice, Inbred C57BL | 28 | 2025 | 258 | 2.640 |
Why?
|
| Mice | 46 | 2025 | 746 | 2.220 |
Why?
|
| Diet, High-Fat | 10 | 2025 | 59 | 2.120 |
Why?
|
| Vaping | 4 | 2025 | 26 | 2.010 |
Why?
|
| Nicotinic Agonists | 7 | 2025 | 38 | 1.990 |
Why?
|
| Proprotein Convertase 2 | 15 | 2016 | 25 | 1.940 |
Why?
|
| Morphine | 7 | 2016 | 47 | 1.940 |
Why?
|
| Humans | 78 | 2025 | 6794 | 1.890 |
Why?
|
| Puberty | 2 | 2025 | 17 | 1.780 |
Why?
|
| Hydrocortisone | 17 | 2020 | 33 | 1.660 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2023 | 279 | 1.630 |
Why?
|
| Female | 57 | 2025 | 4060 | 1.590 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 102 | 1.560 |
Why?
|
| Fatty Liver | 6 | 2024 | 59 | 1.530 |
Why?
|
| Proprotein Convertase 1 | 11 | 2013 | 18 | 1.510 |
Why?
|
| Obesity | 7 | 2025 | 226 | 1.440 |
Why?
|
| Hypothyroidism | 5 | 2025 | 48 | 1.400 |
Why?
|
| Analgesics, Opioid | 6 | 2016 | 58 | 1.370 |
Why?
|
| Pituitary Gland | 15 | 2020 | 40 | 1.350 |
Why?
|
| Triiodothyronine | 5 | 2025 | 54 | 1.320 |
Why?
|
| Brain | 9 | 2016 | 94 | 1.260 |
Why?
|
| Adolescent | 16 | 2025 | 869 | 1.220 |
Why?
|
| Adult | 41 | 2025 | 2113 | 1.210 |
Why?
|
| Smoking | 6 | 2022 | 86 | 1.190 |
Why?
|
| Hormone Replacement Therapy | 2 | 2025 | 17 | 1.080 |
Why?
|
| Aspartic Acid Endopeptidases | 11 | 2001 | 12 | 1.070 |
Why?
|
| Middle Aged | 34 | 2025 | 2108 | 1.050 |
Why?
|
| Morphine Dependence | 3 | 2016 | 9 | 0.970 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2024 | 35 | 0.970 |
Why?
|
| Muscle, Skeletal | 3 | 2025 | 75 | 0.950 |
Why?
|
| Hepatocytes | 7 | 2014 | 85 | 0.920 |
Why?
|
| Triiodothyronine, Reverse | 1 | 2025 | 4 | 0.920 |
Why?
|
| Pro-Opiomelanocortin | 8 | 2013 | 21 | 0.920 |
Why?
|
| Underage Drinking | 1 | 2025 | 7 | 0.920 |
Why?
|
| Insulin Resistance | 7 | 2019 | 74 | 0.910 |
Why?
|
| Carbohydrate Dehydrogenases | 7 | 2019 | 14 | 0.910 |
Why?
|
| Alcohol Drinking | 1 | 2025 | 65 | 0.880 |
Why?
|
| Testosterone | 5 | 2025 | 50 | 0.850 |
Why?
|
| Tobacco Products | 2 | 2025 | 14 | 0.850 |
Why?
|
| Niacinamide | 1 | 2024 | 5 | 0.850 |
Why?
|
| Pyridinium Compounds | 1 | 2024 | 6 | 0.850 |
Why?
|
| Smoking Cessation | 3 | 2023 | 25 | 0.850 |
Why?
|
| Prediabetic State | 4 | 2014 | 28 | 0.840 |
Why?
|
| Dexamethasone | 4 | 2018 | 30 | 0.830 |
Why?
|
| Neurosecretory Systems | 1 | 2024 | 8 | 0.830 |
Why?
|
| Subtilisins | 8 | 2001 | 9 | 0.830 |
Why?
|
| Sex Characteristics | 2 | 2024 | 39 | 0.810 |
Why?
|
| Melatonin | 1 | 2023 | 3 | 0.810 |
Why?
|
| Atherosclerosis | 2 | 2025 | 39 | 0.800 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 13 | 0.790 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 3 | 2013 | 13 | 0.790 |
Why?
|
| Thyrotropin-Releasing Hormone | 10 | 2008 | 19 | 0.790 |
Why?
|
| Receptors, Glucocorticoid | 5 | 2016 | 25 | 0.790 |
Why?
|
| Endoribonucleases | 1 | 2023 | 4 | 0.790 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 11 | 0.780 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 17 | 0.780 |
Why?
|
| Gene Expression Regulation | 7 | 2013 | 120 | 0.780 |
Why?
|
| Oxidative Stress | 10 | 2024 | 102 | 0.770 |
Why?
|
| Corticosterone | 7 | 2019 | 24 | 0.770 |
Why?
|
| Body Weight | 10 | 2016 | 90 | 0.740 |
Why?
|
| Rats | 26 | 2013 | 571 | 0.740 |
Why?
|
| Diet | 2 | 2021 | 111 | 0.740 |
Why?
|
| Protein Precursors | 8 | 2006 | 15 | 0.740 |
Why?
|
| Diabetes Mellitus, Experimental | 6 | 2013 | 29 | 0.730 |
Why?
|
| Insulin | 8 | 2016 | 146 | 0.730 |
Why?
|
| Eating | 2 | 2013 | 31 | 0.710 |
Why?
|
| Behavior, Animal | 3 | 2019 | 30 | 0.700 |
Why?
|
| Mexican Americans | 1 | 2021 | 14 | 0.690 |
Why?
|
| Hyperglycemia | 3 | 2015 | 27 | 0.690 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 13 | 0.690 |
Why?
|
| Narcotics | 2 | 2013 | 16 | 0.690 |
Why?
|
| RNA, Messenger | 14 | 2013 | 190 | 0.680 |
Why?
|
| Life Style | 1 | 2021 | 51 | 0.680 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 8 | 2019 | 16 | 0.670 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 26 | 0.670 |
Why?
|
| Adrenal Glands | 2 | 2020 | 11 | 0.670 |
Why?
|
| Aerosols | 2 | 2025 | 15 | 0.670 |
Why?
|
| Blood Glucose | 8 | 2019 | 188 | 0.660 |
Why?
|
| Pituitary Neoplasms | 6 | 2008 | 14 | 0.660 |
Why?
|
| Ventricular Function, Left | 2 | 2025 | 21 | 0.660 |
Why?
|
| Vitamin D | 3 | 2014 | 45 | 0.650 |
Why?
|
| Health Status Disparities | 1 | 2021 | 83 | 0.640 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2020 | 13 | 0.640 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 165 | 0.620 |
Why?
|
| Stroke Volume | 1 | 2019 | 20 | 0.600 |
Why?
|
| Child | 5 | 2025 | 524 | 0.580 |
Why?
|
| Receptors, Opioid, mu | 2 | 2016 | 19 | 0.570 |
Why?
|
| Mice, Knockout | 12 | 2019 | 150 | 0.560 |
Why?
|
| Human Growth Hormone | 4 | 2008 | 7 | 0.560 |
Why?
|
| Disease Models, Animal | 8 | 2025 | 231 | 0.560 |
Why?
|
| Young Adult | 6 | 2021 | 567 | 0.530 |
Why?
|
| Proprotein Convertases | 11 | 2006 | 14 | 0.520 |
Why?
|
| Adipose Tissue | 5 | 2019 | 69 | 0.520 |
Why?
|
| Protein Processing, Post-Translational | 9 | 2006 | 20 | 0.520 |
Why?
|
| Glucocorticoids | 6 | 2019 | 65 | 0.520 |
Why?
|
| Nociceptive Pain | 1 | 2016 | 4 | 0.490 |
Why?
|
| Sex Factors | 3 | 2025 | 155 | 0.490 |
Why?
|
| Hypopituitarism | 2 | 2008 | 4 | 0.490 |
Why?
|
| Promoter Regions, Genetic | 4 | 2005 | 45 | 0.480 |
Why?
|
| Adrenocorticotropic Hormone | 16 | 2006 | 25 | 0.470 |
Why?
|
| Drug Resistance | 2 | 2015 | 16 | 0.470 |
Why?
|
| Liver | 5 | 2024 | 157 | 0.470 |
Why?
|
| Androgens | 5 | 2014 | 24 | 0.460 |
Why?
|
| Drug Monitoring | 1 | 2015 | 16 | 0.460 |
Why?
|
| Peptide Fragments | 8 | 2012 | 23 | 0.450 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2013 | 282 | 0.450 |
Why?
|
| Mice, Obese | 7 | 2020 | 16 | 0.450 |
Why?
|
| Apoptosis | 4 | 2020 | 179 | 0.440 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 39 | 0.440 |
Why?
|
| Retrospective Studies | 7 | 2020 | 681 | 0.440 |
Why?
|
| Lipolysis | 4 | 2023 | 13 | 0.440 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2018 | 155 | 0.440 |
Why?
|
| Myocytes, Cardiac | 3 | 2020 | 23 | 0.440 |
Why?
|
| Adolescent Development | 2 | 2025 | 15 | 0.440 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2025 | 28 | 0.440 |
Why?
|
| Risk Factors | 4 | 2025 | 767 | 0.430 |
Why?
|
| Hydrogen-Ion Concentration | 6 | 2020 | 34 | 0.410 |
Why?
|
| Endocrine System Diseases | 2 | 2012 | 6 | 0.410 |
Why?
|
| Feeding Behavior | 1 | 2013 | 38 | 0.400 |
Why?
|
| Adiposity | 4 | 2019 | 20 | 0.390 |
Why?
|
| Corticotropin-Releasing Hormone | 12 | 2012 | 21 | 0.390 |
Why?
|
| Diet, Western | 2 | 2025 | 8 | 0.380 |
Why?
|
| Blood Pressure | 2 | 2025 | 112 | 0.380 |
Why?
|
| Aged | 12 | 2025 | 1539 | 0.380 |
Why?
|
| Body Composition | 2 | 2014 | 47 | 0.380 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2016 | 16 | 0.370 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 2 | 2012 | 7 | 0.370 |
Why?
|
| Receptors, Vasopressin | 1 | 2012 | 7 | 0.360 |
Why?
|
| Pyrrolidonecarboxylic Acid | 7 | 2006 | 9 | 0.360 |
Why?
|
| Endopeptidases | 6 | 1993 | 9 | 0.350 |
Why?
|
| Endocrine System | 2 | 2009 | 3 | 0.350 |
Why?
|
| Cholecalciferol | 1 | 2011 | 8 | 0.350 |
Why?
|
| Kidney | 2 | 2025 | 184 | 0.350 |
Why?
|
| Fasting | 1 | 2011 | 31 | 0.350 |
Why?
|
| Narcotic Antagonists | 4 | 2016 | 29 | 0.350 |
Why?
|
| Cotinine | 3 | 2020 | 21 | 0.340 |
Why?
|
| Adenoma | 3 | 2008 | 7 | 0.340 |
Why?
|
| Arginine Vasopressin | 5 | 2012 | 46 | 0.330 |
Why?
|
| Pituitary Gland, Anterior | 4 | 2004 | 17 | 0.330 |
Why?
|
| Prevalence | 5 | 2021 | 259 | 0.330 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2014 | 17 | 0.320 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2007 | 64 | 0.310 |
Why?
|
| Opiate Alkaloids | 1 | 2009 | 3 | 0.310 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 44 | 0.310 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2008 | 20 | 0.310 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 14 | 0.300 |
Why?
|
| Pituitary-Adrenal System | 4 | 2006 | 13 | 0.300 |
Why?
|
| Hypothalamo-Hypophyseal System | 4 | 2006 | 18 | 0.300 |
Why?
|
| United States | 2 | 2025 | 1019 | 0.300 |
Why?
|
| Hypogonadism | 4 | 2012 | 10 | 0.300 |
Why?
|
| Time Factors | 7 | 2015 | 321 | 0.290 |
Why?
|
| Thyroxine | 3 | 2025 | 33 | 0.290 |
Why?
|
| Carcinoma | 2 | 2007 | 13 | 0.290 |
Why?
|
| Vitamin D Deficiency | 2 | 2014 | 24 | 0.290 |
Why?
|
| Antineoplastic Agents | 3 | 2005 | 72 | 0.290 |
Why?
|
| Cells, Cultured | 7 | 2010 | 234 | 0.290 |
Why?
|
| Delta Sleep-Inducing Peptide | 4 | 2000 | 4 | 0.290 |
Why?
|
| Immunohistochemistry | 13 | 2019 | 118 | 0.280 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 2008 | 3 | 0.280 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2025 | 5 | 0.270 |
Why?
|
| Thyroid Hormones | 2 | 2006 | 30 | 0.270 |
Why?
|
| Cell Line | 10 | 2013 | 124 | 0.270 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 3 | 0.270 |
Why?
|
| Parathyroid Neoplasms | 1 | 2007 | 4 | 0.270 |
Why?
|
| Tobacco Use Disorder | 2 | 2023 | 10 | 0.260 |
Why?
|
| Animal Feed | 2 | 2020 | 11 | 0.260 |
Why?
|
| Glycated Hemoglobin A | 4 | 2015 | 65 | 0.260 |
Why?
|
| Phenotype | 2 | 2023 | 91 | 0.250 |
Why?
|
| Up-Regulation | 3 | 2020 | 94 | 0.250 |
Why?
|
| Aminopeptidases | 4 | 1995 | 4 | 0.250 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 9 | 0.250 |
Why?
|
| Immune System | 2 | 2023 | 14 | 0.250 |
Why?
|
| Sulfonamides | 1 | 2006 | 17 | 0.250 |
Why?
|
| Serine Endopeptidases | 5 | 1992 | 10 | 0.250 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 38 | 0.250 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2025 | 15 | 0.240 |
Why?
|
| Weight Gain | 2 | 2016 | 28 | 0.230 |
Why?
|
| Hyperlipidemias | 1 | 2025 | 22 | 0.230 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 140 | 0.230 |
Why?
|
| Chromatography, Liquid | 1 | 2025 | 6 | 0.230 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 2 | 2025 | 5 | 0.230 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2025 | 8 | 0.230 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 50 | 0.230 |
Why?
|
| Sleep Stages | 3 | 1995 | 5 | 0.230 |
Why?
|
| Diabetic Nephropathies | 1 | 2025 | 56 | 0.220 |
Why?
|
| Reward | 3 | 2013 | 18 | 0.220 |
Why?
|
| Sleep, REM | 3 | 2000 | 5 | 0.220 |
Why?
|
| Adolescent Behavior | 1 | 2025 | 43 | 0.220 |
Why?
|
| Marijuana Use | 1 | 2025 | 9 | 0.220 |
Why?
|
| Hypothalamus | 5 | 2010 | 49 | 0.220 |
Why?
|
| Age Factors | 1 | 2025 | 193 | 0.220 |
Why?
|
| Glucagon | 2 | 2005 | 8 | 0.220 |
Why?
|
| Conditioning, Operant | 3 | 2013 | 17 | 0.220 |
Why?
|
| Petrosal Sinus Sampling | 4 | 1997 | 4 | 0.220 |
Why?
|
| High Fructose Corn Syrup | 1 | 2024 | 5 | 0.210 |
Why?
|
| Postmenopause | 2 | 2014 | 10 | 0.210 |
Why?
|
| Ergolines | 1 | 2004 | 1 | 0.210 |
Why?
|
| Hyperprolactinemia | 1 | 2004 | 1 | 0.210 |
Why?
|
| Prolactinoma | 1 | 2004 | 2 | 0.210 |
Why?
|
| Leptin | 2 | 2004 | 21 | 0.210 |
Why?
|
| Mice, Knockout, ApoE | 2 | 2025 | 10 | 0.210 |
Why?
|
| Central Nervous System Cysts | 1 | 2004 | 1 | 0.210 |
Why?
|
| Addison Disease | 2 | 2000 | 2 | 0.210 |
Why?
|
| Pituitary Diseases | 1 | 2004 | 2 | 0.210 |
Why?
|
| Chagas Disease | 1 | 2004 | 4 | 0.210 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2025 | 29 | 0.210 |
Why?
|
| Intracranial Aneurysm | 1 | 2004 | 2 | 0.210 |
Why?
|
| Carotid Arteries | 1 | 2004 | 4 | 0.210 |
Why?
|
| Glucose Tolerance Test | 4 | 2012 | 40 | 0.210 |
Why?
|
| Hypertension | 1 | 2025 | 147 | 0.210 |
Why?
|
| Feedback | 1 | 2023 | 12 | 0.200 |
Why?
|
| Abdominal Fat | 2 | 2014 | 6 | 0.200 |
Why?
|
| Cytokines | 1 | 2023 | 80 | 0.200 |
Why?
|
| Hep G2 Cells | 1 | 2023 | 7 | 0.200 |
Why?
|
| Palmitates | 1 | 2023 | 5 | 0.200 |
Why?
|
| Endocrine Glands | 1 | 2003 | 3 | 0.200 |
Why?
|
| Fatty Acids | 1 | 2023 | 25 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 90 | 0.190 |
Why?
|
| Recombinant Proteins | 7 | 2004 | 45 | 0.180 |
Why?
|
| Depression | 1 | 2023 | 128 | 0.180 |
Why?
|
| Drug Tolerance | 2 | 2016 | 25 | 0.180 |
Why?
|
| Monosaccharide Transport Proteins | 2 | 2013 | 8 | 0.180 |
Why?
|
| Regression Analysis | 2 | 2021 | 66 | 0.180 |
Why?
|
| beta-Endorphin | 4 | 2012 | 15 | 0.180 |
Why?
|
| Transcriptome | 2 | 2019 | 31 | 0.180 |
Why?
|
| Hospital Administrators | 1 | 2021 | 1 | 0.180 |
Why?
|
| Adrenalectomy | 2 | 2020 | 10 | 0.180 |
Why?
|
| Phosphorylation | 3 | 2021 | 73 | 0.170 |
Why?
|
| Epithelial Sodium Channels | 1 | 2021 | 2 | 0.170 |
Why?
|
| Burnout, Professional | 1 | 2021 | 12 | 0.170 |
Why?
|
| Safety-net Providers | 1 | 2021 | 24 | 0.170 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 67 | 0.170 |
Why?
|
| Carcinoma, Verrucous | 1 | 2021 | 1 | 0.170 |
Why?
|
| Buschke-Lowenstein Tumor | 1 | 2021 | 1 | 0.170 |
Why?
|
| Uracil | 1 | 2001 | 2 | 0.170 |
Why?
|
| Obesity, Abdominal | 2 | 2018 | 6 | 0.170 |
Why?
|
| Anus Neoplasms | 1 | 2021 | 3 | 0.170 |
Why?
|
| Analysis of Variance | 5 | 2019 | 63 | 0.170 |
Why?
|
| Blotting, Western | 5 | 2019 | 110 | 0.170 |
Why?
|
| Sleep | 1 | 2000 | 14 | 0.170 |
Why?
|
| Myocardium | 1 | 2020 | 25 | 0.160 |
Why?
|
| Heart | 1 | 2020 | 25 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 28 | 0.160 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2000 | 33 | 0.160 |
Why?
|
| Buffers | 1 | 2020 | 2 | 0.160 |
Why?
|
| Energy Intake | 3 | 2025 | 30 | 0.160 |
Why?
|
| Calcium | 4 | 2007 | 117 | 0.160 |
Why?
|
| Los Angeles | 2 | 2025 | 321 | 0.160 |
Why?
|
| Dietary Fats | 2 | 2011 | 19 | 0.160 |
Why?
|
| Receptors, Cytokine | 1 | 1999 | 1 | 0.160 |
Why?
|
| Receptors, Interleukin-6 | 1 | 1999 | 1 | 0.160 |
Why?
|
| Genes, RAG-1 | 1 | 1999 | 1 | 0.160 |
Why?
|
| Lymphocyte Transfusion | 1 | 1999 | 1 | 0.160 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 1999 | 4 | 0.160 |
Why?
|
| Fetal Tissue Transplantation | 1 | 1999 | 2 | 0.160 |
Why?
|
| Transplantation, Heterologous | 1 | 1999 | 18 | 0.160 |
Why?
|
| Antigens, CD | 1 | 1999 | 21 | 0.160 |
Why?
|
| Circadian Rhythm | 3 | 2000 | 11 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1999 | 38 | 0.150 |
Why?
|
| Graft Rejection | 1 | 1999 | 26 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 33 | 0.150 |
Why?
|
| Apolipoproteins E | 1 | 2019 | 6 | 0.150 |
Why?
|
| Sexuality | 2 | 2014 | 16 | 0.150 |
Why?
|
| Inhalation Exposure | 1 | 2019 | 9 | 0.150 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 9 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 93 | 0.150 |
Why?
|
| Triglycerides | 3 | 2014 | 58 | 0.150 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 45 | 0.150 |
Why?
|
| Pancreas | 1 | 2000 | 144 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 65 | 0.150 |
Why?
|
| Body Mass Index | 6 | 2014 | 145 | 0.150 |
Why?
|
| Mutation | 1 | 2019 | 97 | 0.150 |
Why?
|
| Drinking Behavior | 1 | 1998 | 5 | 0.140 |
Why?
|
| Naloxone | 2 | 2016 | 22 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 170 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 58 | 0.140 |
Why?
|
| Luciferases | 3 | 2005 | 10 | 0.140 |
Why?
|
| Blotting, Northern | 4 | 2003 | 25 | 0.140 |
Why?
|
| Bridged Bicyclo Compounds | 1 | 2018 | 4 | 0.140 |
Why?
|
| Benzamides | 1 | 2018 | 11 | 0.140 |
Why?
|
| Inflammation | 2 | 2020 | 143 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 98 | 0.140 |
Why?
|
| Lipids | 2 | 1999 | 35 | 0.140 |
Why?
|
| Pyroglutamyl-Peptidase I | 3 | 1986 | 3 | 0.140 |
Why?
|
| Glucagon-Like Peptide 1 | 3 | 2010 | 11 | 0.130 |
Why?
|
| Double-Blind Method | 2 | 2012 | 101 | 0.130 |
Why?
|
| Fatty Acids, Nonesterified | 4 | 2020 | 19 | 0.130 |
Why?
|
| Carbohydrates | 1 | 1996 | 5 | 0.130 |
Why?
|
| Radioimmunoassay | 6 | 2008 | 26 | 0.130 |
Why?
|
| Hyperthyroidism | 2 | 2006 | 18 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2018 | 246 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 420 | 0.130 |
Why?
|
| Naltrexone | 2 | 2013 | 16 | 0.120 |
Why?
|
| Streptozocin | 3 | 2001 | 11 | 0.120 |
Why?
|
| Gene Expression | 2 | 2008 | 77 | 0.120 |
Why?
|
| Medical Records | 2 | 2015 | 23 | 0.120 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 2 | 2006 | 8 | 0.120 |
Why?
|
| Mice, 129 Strain | 1 | 2016 | 5 | 0.120 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2016 | 10 | 0.120 |
Why?
|
| RNA, Antisense | 1 | 1996 | 1 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2015 | 109 | 0.120 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 1 | 0.120 |
Why?
|
| Dyspareunia | 1 | 2015 | 2 | 0.120 |
Why?
|
| Models, Biological | 3 | 2016 | 64 | 0.120 |
Why?
|
| Uterine Prolapse | 1 | 2015 | 5 | 0.120 |
Why?
|
| Urogenital Surgical Procedures | 1 | 2015 | 2 | 0.120 |
Why?
|
| Surgical Mesh | 1 | 2015 | 4 | 0.120 |
Why?
|
| Dietary Supplements | 2 | 2014 | 44 | 0.120 |
Why?
|
| Urban Health Services | 1 | 2015 | 17 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 25 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 84 | 0.110 |
Why?
|
| Prolactin | 2 | 2004 | 23 | 0.110 |
Why?
|
| Tissue Distribution | 4 | 2006 | 27 | 0.110 |
Why?
|
| Bacillus anthracis | 1 | 1995 | 1 | 0.110 |
Why?
|
| Antigens, Bacterial | 1 | 1995 | 2 | 0.110 |
Why?
|
| Glucose | 2 | 2005 | 50 | 0.110 |
Why?
|
| Bacterial Toxins | 1 | 1995 | 6 | 0.110 |
Why?
|
| Parathyroid Hormone | 2 | 2007 | 44 | 0.110 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2005 | 7 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 26 | 0.110 |
Why?
|
| Transfection | 3 | 2008 | 56 | 0.110 |
Why?
|
| Pain Measurement | 3 | 2010 | 51 | 0.110 |
Why?
|
| Aging | 2 | 2013 | 105 | 0.110 |
Why?
|
| Caspase 2 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Hysterectomy | 1 | 2014 | 12 | 0.110 |
Why?
|
| Body Temperature | 1 | 1994 | 3 | 0.110 |
Why?
|
| Cattle | 7 | 1995 | 13 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 26 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 79 | 0.110 |
Why?
|
| Molecular Sequence Data | 8 | 2005 | 70 | 0.100 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2014 | 10 | 0.100 |
Why?
|
| Carboxypeptidases | 1 | 1993 | 1 | 0.100 |
Why?
|
| Anorexia | 1 | 2013 | 8 | 0.100 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2013 | 1 | 0.100 |
Why?
|
| KATP Channels | 1 | 2013 | 1 | 0.100 |
Why?
|
| Mitochondria | 1 | 2014 | 37 | 0.100 |
Why?
|
| Pain Threshold | 1 | 2013 | 5 | 0.100 |
Why?
|
| Drug Implants | 1 | 2013 | 16 | 0.100 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 14 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2013 | 17 | 0.100 |
Why?
|
| Neurons | 3 | 2006 | 50 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2008 | 108 | 0.100 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 2 | 2025 | 7 | 0.100 |
Why?
|
| Interleukin-6 | 3 | 2014 | 45 | 0.100 |
Why?
|
| Biomarkers | 4 | 2014 | 214 | 0.100 |
Why?
|
| Antiporters | 1 | 2013 | 4 | 0.100 |
Why?
|
| Islets of Langerhans | 2 | 2005 | 11 | 0.100 |
Why?
|
| Tretinoin | 2 | 2005 | 30 | 0.100 |
Why?
|
| Protease Inhibitors | 5 | 1995 | 11 | 0.100 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 10 | 0.100 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 21 | 0.100 |
Why?
|
| Reference Values | 5 | 2009 | 56 | 0.090 |
Why?
|
| Adipocytes | 3 | 2018 | 31 | 0.090 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2012 | 3 | 0.090 |
Why?
|
| Pyrrolidines | 1 | 2012 | 4 | 0.090 |
Why?
|
| Pyrroles | 1 | 2012 | 4 | 0.090 |
Why?
|
| Cocaine | 1 | 2012 | 22 | 0.090 |
Why?
|
| Base Sequence | 3 | 2004 | 65 | 0.090 |
Why?
|
| Indoles | 1 | 2012 | 11 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2012 | 17 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2012 | 27 | 0.090 |
Why?
|
| Rats, Wistar | 3 | 2013 | 55 | 0.090 |
Why?
|
| Mifepristone | 2 | 2016 | 8 | 0.090 |
Why?
|
| African Americans | 1 | 2014 | 264 | 0.080 |
Why?
|
| Animals, Newborn | 3 | 2020 | 112 | 0.080 |
Why?
|
| Analgesia | 1 | 2010 | 16 | 0.080 |
Why?
|
| Gene Deletion | 2 | 2001 | 17 | 0.080 |
Why?
|
| Adrenocortical Hyperfunction | 1 | 2010 | 2 | 0.080 |
Why?
|
| Opioid Peptides | 1 | 2010 | 17 | 0.080 |
Why?
|
| Saliva | 1 | 2010 | 7 | 0.080 |
Why?
|
| Dipeptides | 3 | 1986 | 6 | 0.080 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2010 | 2 | 0.080 |
Why?
|
| Insulin-Secreting Cells | 1 | 2010 | 4 | 0.080 |
Why?
|
| Enkephalins | 2 | 2010 | 11 | 0.080 |
Why?
|
| Regeneration | 1 | 2010 | 5 | 0.080 |
Why?
|
| Kinetics | 6 | 2005 | 69 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 29 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2007 | 500 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2009 | 17 | 0.080 |
Why?
|
| Hair | 1 | 2009 | 3 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 8 | 1996 | 18 | 0.070 |
Why?
|
| Growth Inhibitors | 2 | 1999 | 3 | 0.070 |
Why?
|
| Lymphokines | 2 | 1999 | 8 | 0.070 |
Why?
|
| Oligomenorrhea | 1 | 2008 | 2 | 0.070 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2008 | 5 | 0.070 |
Why?
|
| Hirsutism | 1 | 2008 | 4 | 0.070 |
Why?
|
| Biological Availability | 1 | 2008 | 8 | 0.070 |
Why?
|
| ROC Curve | 1 | 2008 | 28 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 9 | 0.070 |
Why?
|
| Reaction Time | 1 | 2008 | 12 | 0.070 |
Why?
|
| Carbenoxolone | 1 | 2008 | 2 | 0.070 |
Why?
|
| Deoxyglucose | 1 | 2008 | 4 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2008 | 16 | 0.070 |
Why?
|
| Homeostasis | 1 | 2008 | 40 | 0.070 |
Why?
|
| Substrate Specificity | 5 | 1995 | 10 | 0.070 |
Why?
|
| Pain | 1 | 2008 | 38 | 0.070 |
Why?
|
| Amino Acid Sequence | 6 | 2005 | 38 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2020 | 10 | 0.070 |
Why?
|
| Parathyroidectomy | 1 | 2007 | 3 | 0.070 |
Why?
|
| Thyroidectomy | 1 | 2007 | 6 | 0.070 |
Why?
|
| Hypercalcemia | 1 | 2007 | 11 | 0.070 |
Why?
|
| Growth Hormone | 2 | 2000 | 25 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2007 | 50 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2006 | 167 | 0.060 |
Why?
|
| Creatinine | 1 | 2007 | 48 | 0.060 |
Why?
|
| Pregnancy | 3 | 2020 | 599 | 0.060 |
Why?
|
| Bone Density | 2 | 2008 | 25 | 0.060 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2006 | 2 | 0.060 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2006 | 2 | 0.060 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2006 | 2 | 0.060 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2006 | 3 | 0.060 |
Why?
|
| Liver X Receptors | 1 | 2006 | 3 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2004 | 13 | 0.060 |
Why?
|
| Pyroglutamate Hydrolase | 1 | 1986 | 1 | 0.060 |
Why?
|
| Amidohydrolases | 1 | 1986 | 2 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 59 | 0.060 |
Why?
|
| Locomotion | 1 | 2006 | 6 | 0.060 |
Why?
|
| Spatial Behavior | 1 | 2006 | 4 | 0.060 |
Why?
|
| Choice Behavior | 1 | 2006 | 11 | 0.060 |
Why?
|
| Neurophysins | 1 | 2005 | 2 | 0.060 |
Why?
|
| Oxytocin | 1 | 2005 | 6 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 5 | 0.060 |
Why?
|
| Retinoid X Receptor beta | 1 | 2005 | 2 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2005 | 8 | 0.060 |
Why?
|
| Response Elements | 1 | 2005 | 8 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 15 | 0.060 |
Why?
|
| Hippocampus | 1 | 2005 | 19 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 40 | 0.060 |
Why?
|
| Thyroid Hormone Receptors alpha | 1 | 2005 | 9 | 0.060 |
Why?
|
| Cheek | 1 | 2004 | 3 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 72 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 12 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2004 | 2 | 0.050 |
Why?
|
| Trypanosoma cruzi | 1 | 2004 | 4 | 0.050 |
Why?
|
| RNA Interference | 2 | 2014 | 11 | 0.050 |
Why?
|
| Radiography | 1 | 2004 | 20 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 2 | 1995 | 18 | 0.050 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2004 | 13 | 0.050 |
Why?
|
| Self Administration | 2 | 2013 | 6 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2023 | 7 | 0.050 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 2003 | 1 | 0.050 |
Why?
|
| Public Health | 1 | 2023 | 40 | 0.050 |
Why?
|
| Leukemia Inhibitory Factor | 2 | 1999 | 2 | 0.050 |
Why?
|
| Plasmids | 2 | 2000 | 17 | 0.050 |
Why?
|
| Musculoskeletal Physiological Phenomena | 1 | 2002 | 1 | 0.050 |
Why?
|
| Phosphates | 1 | 2002 | 13 | 0.050 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2002 | 23 | 0.050 |
Why?
|
| Smokers | 1 | 2022 | 8 | 0.050 |
Why?
|
| Cognition | 1 | 2002 | 30 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2001 | 2 | 0.050 |
Why?
|
| Spleen | 1 | 2001 | 13 | 0.050 |
Why?
|
| Osmolar Concentration | 2 | 2004 | 47 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 82 | 0.040 |
Why?
|
| Spironolactone | 1 | 2021 | 3 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 73 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 27 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2021 | 77 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2001 | 3 | 0.040 |
Why?
|
| Retinoid X Receptors | 1 | 2001 | 7 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 10 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2001 | 12 | 0.040 |
Why?
|
| Oligonucleotides | 1 | 2001 | 5 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 13 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2001 | 13 | 0.040 |
Why?
|
| Mecamylamine | 1 | 2020 | 8 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 18 | 0.040 |
Why?
|
| Imidazoles | 1 | 2020 | 13 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2020 | 9 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2020 | 10 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 19 | 0.040 |
Why?
|
| Pyridines | 1 | 2020 | 24 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 21 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2000 | 27 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 24 | 0.040 |
Why?
|
| Electrophoresis | 1 | 2000 | 3 | 0.040 |
Why?
|
| Antithyroid Agents | 1 | 2000 | 5 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 15 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2020 | 15 | 0.040 |
Why?
|
| Isotretinoin | 1 | 2000 | 4 | 0.040 |
Why?
|
| Seasonal Affective Disorder | 1 | 2000 | 1 | 0.040 |
Why?
|
| Multiple Chemical Sensitivity | 1 | 2000 | 1 | 0.040 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2000 | 2 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2001 | 53 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2021 | 78 | 0.040 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2000 | 2 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 87 | 0.040 |
Why?
|
| Proinsulin | 1 | 2000 | 1 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 156 | 0.040 |
Why?
|
| Receptors, OSM-LIF | 1 | 1999 | 1 | 0.040 |
Why?
|
| Leukemia Inhibitory Factor Receptor alpha Subunit | 1 | 1999 | 1 | 0.040 |
Why?
|
| Cell Extracts | 1 | 1999 | 2 | 0.040 |
Why?
|
| Cytokine Receptor gp130 | 1 | 1999 | 3 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 184 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 1999 | 3 | 0.040 |
Why?
|
| Swine | 1 | 1999 | 8 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 41 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 143 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 1 | 1999 | 2 | 0.040 |
Why?
|
| Lipodystrophy | 1 | 1999 | 3 | 0.040 |
Why?
|
| Hormones | 1 | 1999 | 11 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 12 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 14 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 27 | 0.040 |
Why?
|
| HIV-1 | 1 | 1999 | 36 | 0.040 |
Why?
|
| Molecular Weight | 2 | 1995 | 7 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 29 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 1998 | 28 | 0.040 |
Why?
|
| Mammals | 2 | 1995 | 8 | 0.040 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2018 | 7 | 0.030 |
Why?
|
| Arvicolinae | 1 | 1997 | 1 | 0.030 |
Why?
|
| Sirtuin 1 | 1 | 2016 | 8 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 2016 | 10 | 0.030 |
Why?
|
| Lipoproteins | 1 | 1996 | 7 | 0.030 |
Why?
|
| Caspases | 1 | 2016 | 29 | 0.030 |
Why?
|
| Pedigree | 2 | 2013 | 7 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 1994 | 45 | 0.030 |
Why?
|
| Cholesterol | 1 | 1996 | 37 | 0.030 |
Why?
|
| Luteinizing Hormone | 2 | 2008 | 19 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2008 | 15 | 0.030 |
Why?
|
| Hormone Antagonists | 1 | 2016 | 4 | 0.030 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 5 | 0.030 |
Why?
|
| Sheep | 1 | 1996 | 132 | 0.030 |
Why?
|
| Adipogenesis | 1 | 2016 | 13 | 0.030 |
Why?
|
| Phenanthrolines | 2 | 1986 | 2 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1996 | 10 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1986 | 49 | 0.030 |
Why?
|
| DNA Primers | 1 | 1996 | 23 | 0.030 |
Why?
|
| Endometrium | 1 | 1996 | 24 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1995 | 1 | 0.030 |
Why?
|
| Eye | 1 | 1995 | 14 | 0.030 |
Why?
|
| Retinitis | 1 | 1995 | 16 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1995 | 9 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 55 | 0.030 |
Why?
|
| Cell Membrane | 1 | 1995 | 54 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 1995 | 28 | 0.030 |
Why?
|
| Xenopus laevis | 1 | 1995 | 5 | 0.030 |
Why?
|
| Central Nervous System | 1 | 1995 | 8 | 0.030 |
Why?
|
| Uveitis | 1 | 1995 | 53 | 0.030 |
Why?
|
| Membranes | 1 | 1995 | 2 | 0.030 |
Why?
|
| Narcolepsy | 1 | 1995 | 1 | 0.030 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1995 | 5 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2014 | 6 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 16 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 268 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 1994 | 16 | 0.030 |
Why?
|
| Culture Media | 1 | 1994 | 3 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 10 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1994 | 1 | 0.030 |
Why?
|
| Arousal | 1 | 2014 | 3 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 19 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2014 | 9 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 36 | 0.030 |
Why?
|
| HIV Infections | 1 | 1999 | 432 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2014 | 2 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 3 | 0.030 |
Why?
|
| Enzymes | 1 | 1993 | 5 | 0.030 |
Why?
|
| Pyrazines | 1 | 2014 | 17 | 0.030 |
Why?
|
| Reinforcement Schedule | 1 | 2013 | 2 | 0.030 |
Why?
|
| Extinction, Psychological | 1 | 2013 | 2 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 6 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 15 | 0.030 |
Why?
|
| Cataract | 1 | 1993 | 20 | 0.030 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1993 | 2 | 0.030 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Dopamine | 1 | 2013 | 12 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2014 | 100 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 22 | 0.030 |
Why?
|
| Nucleus Accumbens | 1 | 2013 | 9 | 0.030 |
Why?
|
| Ovary | 1 | 1993 | 19 | 0.030 |
Why?
|
| Genes, Fungal | 1 | 1993 | 2 | 0.030 |
Why?
|
| Disease Progression | 2 | 2009 | 170 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2013 | 6 | 0.020 |
Why?
|
| Gluconeogenesis | 1 | 2013 | 4 | 0.020 |
Why?
|
| Puberty, Delayed | 1 | 1992 | 2 | 0.020 |
Why?
|
| Gonadotropins | 1 | 1992 | 2 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 57 | 0.020 |
Why?
|
| Thyrotropin | 1 | 1993 | 51 | 0.020 |
Why?
|
| Hyperaldosteronism | 1 | 1992 | 2 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1992 | 2 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1992 | 57 | 0.020 |
Why?
|
| Oligopeptides | 2 | 1993 | 4 | 0.020 |
Why?
|
| Swimming | 1 | 2010 | 5 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2010 | 9 | 0.020 |
Why?
|
| Dynorphins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 21 | 0.020 |
Why?
|
| Nociceptors | 1 | 2010 | 9 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 43 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 3 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 15 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 23 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 11 | 0.020 |
Why?
|
| Immunoassay | 1 | 2009 | 8 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 118 | 0.020 |
Why?
|
| Premenopause | 1 | 2008 | 6 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 2 | 2004 | 14 | 0.020 |
Why?
|
| Edetic Acid | 1 | 1986 | 3 | 0.020 |
Why?
|
| Median Eminence | 1 | 2006 | 7 | 0.020 |
Why?
|
| Cycloheximide | 1 | 1986 | 5 | 0.020 |
Why?
|
| Proline | 1 | 1986 | 5 | 0.020 |
Why?
|
| Chromogenic Compounds | 1 | 1985 | 1 | 0.010 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 1985 | 3 | 0.010 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 1985 | 2 | 0.010 |
Why?
|
| Pyrrolidinones | 1 | 1985 | 2 | 0.010 |
Why?
|
| Proglucagon | 1 | 2005 | 1 | 0.010 |
Why?
|
| Proteome | 1 | 2005 | 2 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 40 | 0.010 |
Why?
|
| Furin | 2 | 1995 | 2 | 0.010 |
Why?
|
| Tissue Adhesives | 1 | 2004 | 1 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 2004 | 5 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 13 | 0.010 |
Why?
|
| Leucyl Aminopeptidase | 1 | 1984 | 1 | 0.010 |
Why?
|
| Metalloproteins | 1 | 1984 | 2 | 0.010 |
Why?
|
| Cathepsin B | 1 | 1984 | 3 | 0.010 |
Why?
|
| Cathepsin D | 1 | 1984 | 2 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 1984 | 2 | 0.010 |
Why?
|
| Cathepsins | 1 | 1984 | 12 | 0.010 |
Why?
|
| Estradiol | 1 | 2004 | 57 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 48 | 0.010 |
Why?
|
| Sulfamethoxazole | 1 | 1984 | 1 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 72 | 0.010 |
Why?
|
| Turner Syndrome | 1 | 2001 | 2 | 0.010 |
Why?
|
| Comorbidity | 1 | 2000 | 147 | 0.010 |
Why?
|
| Transcortin | 1 | 1999 | 1 | 0.010 |
Why?
|
| Receptors, Leptin | 1 | 1998 | 5 | 0.010 |
Why?
|
| Fetus | 1 | 1998 | 125 | 0.010 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 1997 | 1 | 0.010 |
Why?
|
| Adrenal Gland Diseases | 1 | 1997 | 3 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1997 | 15 | 0.010 |
Why?
|
| Species Specificity | 1 | 1997 | 17 | 0.010 |
Why?
|
| Organ Size | 1 | 1997 | 31 | 0.010 |
Why?
|
| Dehydroepiandrosterone | 1 | 1996 | 6 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1997 | 60 | 0.010 |
Why?
|
| Menstrual Cycle | 1 | 1996 | 11 | 0.010 |
Why?
|
| Zinc Compounds | 1 | 1995 | 1 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1997 | 331 | 0.010 |
Why?
|
| Chlorides | 1 | 1995 | 12 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1995 | 4 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1995 | 16 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1995 | 5 | 0.010 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1995 | 1 | 0.010 |
Why?
|
| Fishes | 1 | 1995 | 9 | 0.010 |
Why?
|
| Somatostatin | 1 | 1995 | 10 | 0.010 |
Why?
|
| Follicular Fluid | 1 | 1994 | 1 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1994 | 10 | 0.010 |
Why?
|
| Lens Capsule, Crystalline | 1 | 1993 | 2 | 0.010 |
Why?
|
| Autoradiography | 1 | 1993 | 1 | 0.010 |
Why?
|
| Corpus Luteum | 1 | 1993 | 1 | 0.010 |
Why?
|
| Theca Cells | 1 | 1993 | 2 | 0.010 |
Why?
|
| Ovarian Follicle | 1 | 1993 | 2 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1993 | 11 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1993 | 11 | 0.010 |
Why?
|
| beta-Lipotropin | 1 | 1993 | 1 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1993 | 3 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1993 | 3 | 0.010 |
Why?
|
| Granulosa Cells | 1 | 1993 | 12 | 0.010 |
Why?
|
| Octreotide | 1 | 1993 | 1 | 0.010 |
Why?
|
| Pleural Effusion, Malignant | 1 | 1993 | 1 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1993 | 5 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1993 | 22 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1993 | 11 | 0.010 |
Why?
|
| Alopecia | 1 | 1992 | 1 | 0.010 |
Why?
|
| Deafness | 1 | 1992 | 6 | 0.010 |
Why?
|
| Syndrome | 1 | 1992 | 32 | 0.010 |
Why?
|
| Intellectual Disability | 1 | 1992 | 7 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1992 | 6 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1992 | 5 | 0.010 |
Why?
|
| alpha-MSH | 1 | 1992 | 3 | 0.010 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1992 | 4 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1993 | 63 | 0.010 |
Why?
|